Evidence map›Paper›PMID 38868522›Full record

ArticleVaccine: X2024

Evaluation of the immunoprotective power of a multiple antigenic peptide against Aah II toxin of

Safouane M Benazzouz, Nesrine Benlouahmia, Karima Bouhadida, Meriem Benlamara, Naziha Arezki, Oum El Kheir Sadeddine, Mourad Issad, Nabila Attal, Kamel Mansouri, Fawzi Derrar and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Safouane M BenazzouzLaboratoire de Pharmacologie, Faculté de Pharmacie d'Alger, Université d'Alger 1. 8 Rue du Lieutenant Mohamed Benarfa, El Biar, Alger 16000, Algeria.
Nesrine BenlouahmiaLaboratoire des Sérums Thérapeutiques, Département des Produits Biologiques Humains, Direction de la Production, Institut Pasteur d'Algérie. Rue du Petit Staoueli, Dely Ibrahim, Alger 16320, Algeria.
Karima BouhadidaLaboratoire des Sérums Thérapeutiques, Département des Produits Biologiques Humains, Direction de la Production, Institut Pasteur d'Algérie. Rue du Petit Staoueli, Dely Ibrahim, Alger 16320, Algeria.
Meriem BenlamaraLaboratoire des Sérums Thérapeutiques, Département des Produits Biologiques Humains, Direction de la Production, Institut Pasteur d'Algérie. Rue du Petit Staoueli, Dely Ibrahim, Alger 16320, Algeria.
Naziha ArezkiLaboratoire des Sérums Thérapeutiques, Département des Produits Biologiques Humains, Direction de la Production, Institut Pasteur d'Algérie. Rue du Petit Staoueli, Dely Ibrahim, Alger 16320, Algeria.
Oum El Kheir SadeddineLaboratoire des Sérums Thérapeutiques, Département des Produits Biologiques Humains, Direction de la Production, Institut Pasteur d'Algérie. Rue du Petit Staoueli, Dely Ibrahim, Alger 16320, Algeria.
Mourad IssadLaboratoire des Vaccins Viraux Humains, Département des Produits Biologiques Humains, Direction de la Production, Institut Pasteur d'Algérie, Rue du Petit Staoueli, Dely Ibrahim, Alger 16320, Algeria.
Nabila AttalLaboratoire d'Immunologie, Faculté de Pharmacie d'Alger, Université d'Alger 1. 8 Rue du Lieutenant Mohamed Benarfa, El Biar, Alger 16000, Algeria.
Kamel MansouriLaboratoire de Pharmacologie, Faculté de Pharmacie d'Alger, Université d'Alger 1. 8 Rue du Lieutenant Mohamed Benarfa, El Biar, Alger 16000, Algeria.
Fawzi DerrarLaboratoire de la Grippe et autres Virus Respiratoires, Département de Virologie, Direction des Laboratoires, de la Recherche et du Développement, Institut Pasteur d'Algérie. Rue du Petit Staoueli, Dely Ibrahim, Alger 16320, Algeria.
Reda DjidjikLaboratoire d'Immunologie, Faculté de Pharmacie d'Alger, Université d'Alger 1. 8 Rue du Lieutenant Mohamed Benarfa, El Biar, Alger 16000, Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scorpion envenoming (SE) is a public health problem in developing countries. In Algeria, the population exposed to the risk of SE was estimated at 86.45% in 2019. Thus, the development of a vaccine to protect the exposed population against scorpion toxins would be a major advance in the fight against this disease. This work aimed to evaluate the immunoprotective effect of a Multiple Antigenic Peptide against the Aah II toxin of

Indexed as

Androctonus australis hectorImmunotherapyMultiple Antigenic PeptideScorpion toxin

Identifiers

PMID38868522
PMCPMC11167365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.